Polymer delivery of camptothecin against 9L gliosarcoma: Release, distribution, and efficacy

Phillip B. Storm, John L. Moriarity, Betty Tyler, Peter C. Burger, Henry Brem, Jon Weingart

Research output: Contribution to journalArticle

Abstract

Camptothecin is a potent antineoplastic agent that has shown efficacy against multiple tumor lines in vitro; unfortunately, systemic toxicity has limited its in vivo efficacy. This is the first study to investigate the release, biodistribution, and efficacy of camptothecin from a biodegradable polyanhydride polymer. Tritiated camptothecin was incorporated into biodegradable polymers that were implanted intracranially in 16 male Fischer 344 rats and the animals were followed up to 21 days post-implant. A concentration of 11-45 μg of camptothecin-sodium/mg brain tissue was within a 3 mm radius of the polymer disc, with levels of 0.1 μg at the outermost margin of the rat brain, 7 mm from the site of implantation. These tissue concentrations are within the therapeutic ranges for human and rat glioma lines tested against camptothecin-sodium in vitro. The in vivo efficacy of camptothecin-sodium was evaluated with male Fischer 344 rats implanted intracranially with 9L gliosarcoma and compared with the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). The animals were divided into four groups. Group 1 (control) had a median survival of 17 days. Group 2 (3.8% BCNU polymer) had a median survival of 23 days (P = 0.006). Group 3 (20% camptothecin polymer) had a median survival of 25 days (P = 0.023). Group 4 (50% camptothecin polymer) had a median survival of 69 days (P <0.001). Drug loadings of 20% and 50% camptothecin released intact camptothecin for up to 1000 h in vitro. We conclude that the biodegradable polymer p(CPP : SA) releases camptothecin-sodium, produces tumoricidal tissue levels, results in little or no systemic toxicity, and prolongs survival in a rat glioma model.

Original languageEnglish (US)
Pages (from-to)209-217
Number of pages9
JournalJournal of Neuro-Oncology
Volume56
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Gliosarcoma
Camptothecin
Polymers
Carmustine
Sodium
Survival
Inbred F344 Rats
Glioma
Polyanhydrides
Brain
Antineoplastic Agents

Keywords

  • Blood-brain barrier
  • Camptothecin
  • Distribution
  • Glioma
  • Polymer

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Polymer delivery of camptothecin against 9L gliosarcoma : Release, distribution, and efficacy. / Storm, Phillip B.; Moriarity, John L.; Tyler, Betty; Burger, Peter C.; Brem, Henry; Weingart, Jon.

In: Journal of Neuro-Oncology, Vol. 56, No. 3, 2002, p. 209-217.

Research output: Contribution to journalArticle

@article{8e9dcae19f2d4600bc9c6b99f66aa48e,
title = "Polymer delivery of camptothecin against 9L gliosarcoma: Release, distribution, and efficacy",
abstract = "Camptothecin is a potent antineoplastic agent that has shown efficacy against multiple tumor lines in vitro; unfortunately, systemic toxicity has limited its in vivo efficacy. This is the first study to investigate the release, biodistribution, and efficacy of camptothecin from a biodegradable polyanhydride polymer. Tritiated camptothecin was incorporated into biodegradable polymers that were implanted intracranially in 16 male Fischer 344 rats and the animals were followed up to 21 days post-implant. A concentration of 11-45 μg of camptothecin-sodium/mg brain tissue was within a 3 mm radius of the polymer disc, with levels of 0.1 μg at the outermost margin of the rat brain, 7 mm from the site of implantation. These tissue concentrations are within the therapeutic ranges for human and rat glioma lines tested against camptothecin-sodium in vitro. The in vivo efficacy of camptothecin-sodium was evaluated with male Fischer 344 rats implanted intracranially with 9L gliosarcoma and compared with the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). The animals were divided into four groups. Group 1 (control) had a median survival of 17 days. Group 2 (3.8{\%} BCNU polymer) had a median survival of 23 days (P = 0.006). Group 3 (20{\%} camptothecin polymer) had a median survival of 25 days (P = 0.023). Group 4 (50{\%} camptothecin polymer) had a median survival of 69 days (P <0.001). Drug loadings of 20{\%} and 50{\%} camptothecin released intact camptothecin for up to 1000 h in vitro. We conclude that the biodegradable polymer p(CPP : SA) releases camptothecin-sodium, produces tumoricidal tissue levels, results in little or no systemic toxicity, and prolongs survival in a rat glioma model.",
keywords = "Blood-brain barrier, Camptothecin, Distribution, Glioma, Polymer",
author = "Storm, {Phillip B.} and Moriarity, {John L.} and Betty Tyler and Burger, {Peter C.} and Henry Brem and Jon Weingart",
year = "2002",
doi = "10.1023/A:1015003232713",
language = "English (US)",
volume = "56",
pages = "209--217",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Polymer delivery of camptothecin against 9L gliosarcoma

T2 - Release, distribution, and efficacy

AU - Storm, Phillip B.

AU - Moriarity, John L.

AU - Tyler, Betty

AU - Burger, Peter C.

AU - Brem, Henry

AU - Weingart, Jon

PY - 2002

Y1 - 2002

N2 - Camptothecin is a potent antineoplastic agent that has shown efficacy against multiple tumor lines in vitro; unfortunately, systemic toxicity has limited its in vivo efficacy. This is the first study to investigate the release, biodistribution, and efficacy of camptothecin from a biodegradable polyanhydride polymer. Tritiated camptothecin was incorporated into biodegradable polymers that were implanted intracranially in 16 male Fischer 344 rats and the animals were followed up to 21 days post-implant. A concentration of 11-45 μg of camptothecin-sodium/mg brain tissue was within a 3 mm radius of the polymer disc, with levels of 0.1 μg at the outermost margin of the rat brain, 7 mm from the site of implantation. These tissue concentrations are within the therapeutic ranges for human and rat glioma lines tested against camptothecin-sodium in vitro. The in vivo efficacy of camptothecin-sodium was evaluated with male Fischer 344 rats implanted intracranially with 9L gliosarcoma and compared with the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). The animals were divided into four groups. Group 1 (control) had a median survival of 17 days. Group 2 (3.8% BCNU polymer) had a median survival of 23 days (P = 0.006). Group 3 (20% camptothecin polymer) had a median survival of 25 days (P = 0.023). Group 4 (50% camptothecin polymer) had a median survival of 69 days (P <0.001). Drug loadings of 20% and 50% camptothecin released intact camptothecin for up to 1000 h in vitro. We conclude that the biodegradable polymer p(CPP : SA) releases camptothecin-sodium, produces tumoricidal tissue levels, results in little or no systemic toxicity, and prolongs survival in a rat glioma model.

AB - Camptothecin is a potent antineoplastic agent that has shown efficacy against multiple tumor lines in vitro; unfortunately, systemic toxicity has limited its in vivo efficacy. This is the first study to investigate the release, biodistribution, and efficacy of camptothecin from a biodegradable polyanhydride polymer. Tritiated camptothecin was incorporated into biodegradable polymers that were implanted intracranially in 16 male Fischer 344 rats and the animals were followed up to 21 days post-implant. A concentration of 11-45 μg of camptothecin-sodium/mg brain tissue was within a 3 mm radius of the polymer disc, with levels of 0.1 μg at the outermost margin of the rat brain, 7 mm from the site of implantation. These tissue concentrations are within the therapeutic ranges for human and rat glioma lines tested against camptothecin-sodium in vitro. The in vivo efficacy of camptothecin-sodium was evaluated with male Fischer 344 rats implanted intracranially with 9L gliosarcoma and compared with the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). The animals were divided into four groups. Group 1 (control) had a median survival of 17 days. Group 2 (3.8% BCNU polymer) had a median survival of 23 days (P = 0.006). Group 3 (20% camptothecin polymer) had a median survival of 25 days (P = 0.023). Group 4 (50% camptothecin polymer) had a median survival of 69 days (P <0.001). Drug loadings of 20% and 50% camptothecin released intact camptothecin for up to 1000 h in vitro. We conclude that the biodegradable polymer p(CPP : SA) releases camptothecin-sodium, produces tumoricidal tissue levels, results in little or no systemic toxicity, and prolongs survival in a rat glioma model.

KW - Blood-brain barrier

KW - Camptothecin

KW - Distribution

KW - Glioma

KW - Polymer

UR - http://www.scopus.com/inward/record.url?scp=0036251428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036251428&partnerID=8YFLogxK

U2 - 10.1023/A:1015003232713

DO - 10.1023/A:1015003232713

M3 - Article

C2 - 12061726

AN - SCOPUS:0036251428

VL - 56

SP - 209

EP - 217

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -